Drug Trial Radar · NCT00906399
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,516
Actual
Start
Jun 2009
Primary completion
Oct 2012
Study completion Oct 2013
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- May 21, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year. The secondary objectives of this study are to determine whether peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the progression of disability.
Conditions
- Relapsing Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a)Drug
Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
PlaceboDrug
Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR) at 1 YearTime frame: 1 Year
Locations
178 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Ponte Vedra Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Des Moines, Iowa
Research Site
Lexington, Kentucky
Research Site
Baltimore, Maryland
Research Site
Teaneck, New Jersey
Research Site
Raleigh, North Carolina
Research Site
Akron, Ohio
Research Site
Cleveland, Ohio
Research Site
Franklin, Tennessee
Research Site
Round Rock, Texas
Research Site
Brussels, Belgium
Research Site
Sint-Truiden, Belgium
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
London, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Santiago, Chile
Research Site
Bogotá, Colombia
Research Site
Barranquilla, Atlántico, Colombia
Research Site
Bogota, Cundinamarca, Colombia
Research Site
Osijek, Croatia
Research Site
Zagreb, Croatia
Research Site
Brno, Czechia
Research Site
Olomouc, Czechia
Research Site
Ostrava, Czechia
Research Site
Ostrava - Vitkovice, Czechia
Research Site
Ostrava-Poruba, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Teplice, Czechia
Research Site
Pärnu, Estonia
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.